Benutzer: Gast  Login
Titel:

Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group.

Dokumenttyp:
Journal Article
Autor(en):
Koschmieder, Steffen; Isfort, Susanne; Wolf, Dominik; Heidel, Florian H; Hochhaus, Andreas; Schafhausen, Philippe; Griesshammer, Martin; Wolleschak, Denise; Platzbecker, Uwe; Döhner, Konstanze; Jost, Philipp J; Parmentier, Stefani; Schaich, Markus; von Bubnoff, Nikolas; Stegelmann, Frank; Maurer, Angela; Crysandt, Martina; Gezer, Deniz; Kortmann, Maike; Franklin, Jeremy; Frank, Julia; Hellmich, Martin; Brümmendorf, Tim H
Abstract:
Patients (pts) with polycythemia vera (PV) suffer from pruritus, night sweats, and other symptoms, as well as from thromboembolic complications and progression to post-PV myelofibrosis. Ruxolitinib (RUX) is approved for second-line therapy in high-risk PV pts with hydroxyurea intolerance or resistance. The RuxoBEAT trial (NCT02577926, registered on October 1, 2015, at clinicaltrials.gov) is a multicenter, open-label, two-arm phase-IIb trial with a target population of 380 pts with PV or ET, rand...     »
Zeitschriftentitel:
Ann Hematol
Jahr:
2023
Band / Volume:
102
Heft / Issue:
2
Seitenangaben Beitrag:
349-358
Volltext / DOI:
doi:10.1007/s00277-022-05080-7
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/36564535
Print-ISSN:
0939-5555
TUM Einrichtung:
1605; Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie
 BibTeX